Top

International Journal of Clinical Oncology

Published in:

01-08-2012 | Case Report

Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens

Authors: Claudia Marchetti, Filippo Bellati, Angela Musella, Chiara Napoletano, Giorgia Perniola, Violante Di Donato, Sandro Pignata, Marianna Nuti, Pierluigi Benedetti Panici

Published in: International Journal of Clinical Oncology | Issue 4/2012

Abstract

We present two cases of advanced ovarian cancer treated with neoadjuvant chemotherapy with standard tri-weekly carboplatin and paclitaxel. Therapy was converted to weekly regimens because of disease progression, resulting in disease response. Weekly regimens could overcome drug resistance and this strategy should be attempted before abandoning first-line chemotherapy in favor of palliation.

Jemal A, Siegel R, Xu J et al (2010) Cancer statistics. CA Cancer J Clin 60(5):277–300PubMedCrossRef

Parmar MK, Ledermann JA, Colombo N et al (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505–515CrossRef

Vergote I, Tropé CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953PubMedCrossRef

Gordon AN, Tonda M, Sun S et al (2004) Doxil study 30–49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95(1):1–8PubMedCrossRef

Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331–1338PubMedCrossRef

Napoletano C, Bellati F, Landi R et al (2009) Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med 14:2748–2759CrossRef

Bellati F, Napoletano C, Ruscito I et al (2010) Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs 28(6):887–894PubMedCrossRef

Zhang L, Conejo-Garcia JR, Katsaros D et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203–213PubMedCrossRef

Angioli R, Palaia I, Zullo MA et al (2006) Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol 100(3):455–461PubMedCrossRef

10.

Benedetti Panici P, Perniola G, Angioli R et al (2007) Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: impact of surgery. Int J Gynecol Cancer 17(6):1245–1251PubMedCrossRef

11.

Abu-Rustum NR, Aghajanian C, Barakat RR et al (1997) Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 24:S15-62–S15-67

12.

Wu CH, Yang CH, Lee JN et al (2001) Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects. Int J Gynecol Cancer 11(4):295–299PubMedCrossRef

13.

Markman M, Hall J, Spitz D et al (2002) Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20(9):2365–2369PubMedCrossRef

14.

Havrilesky LJ, Alvarez AA, Sayer RA et al (2003) Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol 88(1):51–57PubMedCrossRef

15.

Watanabe Y, Nakai H, Ueda H et al (2005) Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer. Gynecol Oncol 96(2):323–329PubMedCrossRef

16.

Rose PG, Smrekar M, Fusco N (2005) A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. Gynecol Oncol 96(2):296–300PubMedCrossRef

17.

Sehouli J, Stengel D, Mustea A et al (2008) Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother Pharmacol 61:243–250PubMedCrossRef

18.

Pignata S, Breda E, Scambia G et al (2008) A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol 66(3):229–236PubMedCrossRef

19.

Sharma R, Graham J, Mitchell H et al (2009) Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 100:707–712PubMedCrossRef

20.

Safra T, Menczer J, Bernstein RM et al (2009) Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. Gynecol Oncol 114(2):215–218PubMedCrossRef

21.

Oskay-Ozcelik G, Chekerov R, Sommer H et al (2010) Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology. Gynecol Oncol 116:317–322PubMedCrossRef

22.

Benedetti Panici P, Palaia I, Graziano M et al (2010) Intraperitoneal paclitaxel as consolidation treatment in ovarian cancer patients: a case control study. Oncology 78(1):20–25PubMedCrossRef

23.

Bellati F, Calcagno M, Panici PB (2010) Dose-dense paclitaxel for advanced ovarian cancer. Lancet 375(9711):280PubMedCrossRef

24.

Green DR, Ferguson T, Zitvogel L et al (2009) Immunogenic and tolerogenic cell death. Nat Rev Immunol 9:353–363PubMedCrossRef

25.

Bellati F, Visconti V, Napoletano C et al (2009) Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status. Curr Cancer Drug Targets 9(4):541–565PubMedCrossRef

Title: Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens
Authors: Claudia Marchetti
Filippo Bellati
Angela Musella
Chiara Napoletano
Giorgia Perniola
Violante Di Donato
Sandro Pignata
Marianna Nuti
Pierluigi Benedetti Panici
Publication date: 01-08-2012
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 4/2012
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0300-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Primary retroperitoneal mucinous cystadenocarcinoma with mural nodules: a case report and literature review

Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients

A case of myxofibrosarcoma of the maxilla with difficulty in preoperative diagnosis

Leptomeningeal carcinomatosis associated with gastric cancer

Extraosseous Ewing’s sarcoma of the pancreas

Malignant Brenner tumor of the ovary: analysis of 13 cases

Keynote webinar | Spotlight on antibody–drug conjugates in cancer